Orexo Logo

Orexo

ISIN: SE0000736415 | Ticker: ORX | LEI: 549300LJ5CCWDPTK9Z08
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Orexo

Company Description

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of mental illness and substance use disorders. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for the treatment of opioid use disorder.

- Developed four commercial pharmaceutical products with worldwide approval
- Addresses unmet need within the growing space of mental illness and addiction disorders
- Broad product portfolio and development pipeline of traditional pharma products and digital therapies
- Strategic focus on portfolio expansion through development, licensing and M&A
- Strong cash generation from the business area US Pharma enabling to invest in future growth

Year founded

1995

Served area

Worldwide

Headquarters

Rapsgatan 7E, 75105 Uppsala – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,232,900,000.00 1,273,700,000.00 1,109,000,000.00
Noncurrent Assets N/A 401,300,000.00 408,200,000.00 373,500,000.00
Property Plant And Equipment N/A 47,300,000.00 65,900,000.00 76,100,000.00
Intangible Assets Other Than Goodwill N/A 252,800,000.00 248,900,000.00 217,400,000.00
Deferred Tax Assets N/A 32,700,000.00 33,400,000.00 33,100,000.00
Other Noncurrent Financial Assets N/A 700,000.00 800,000.00 900,000.00
Current Assets N/A 831,600,000.00 865,500,000.00 735,500,000.00
Inventories N/A 108,400,000.00 92,300,000.00 74,600,000.00
Trade And Other Current Receivables N/A 165,200,000.00 214,000,000.00 N/A
Current Trade Receivables N/A N/A 214,000,000.00 246,500,000.00
Current Prepaid Expenses N/A 26,900,000.00 31,100,000.00 36,600,000.00
Other Current Receivables N/A N/A 24,100,000.00 25,900,000.00
Other Current Nonfinancial Assets N/A 25,700,000.00 24,100,000.00 N/A
Cash and cash equivalents 816,800,000.00 505,300,000.00 504,100,000.00 132,200,000.00
Shortterm Deposits Not Classified As Cash Equivalents N/A N/A 0.00 219,600,000.00
Equity And Liabilities N/A 1,232,900,000.00 1,273,700,000.00 1,109,000,000.00
Equity 706,400,000.00 558,500,000.00 349,600,000.00 193,900,000.00
Issued Capital N/A 14,200,000.00 14,200,000.00 14,200,000.00
Retained Earnings N/A -1,256,700,000.00 -1,480,200,000.00 -1,657,900,000.00
Share Premium N/A 1,814,400,000.00 1,816,000,000.00 1,815,900,000.00
Other Reserves N/A -13,400,000.00 -400,000.00 N/A
Liabilities N/A 674,400,000.00 924,100,000.00 N/A
Noncurrent Liabilities N/A 73,100,000.00 543,900,000.00 529,200,000.00
Other Longterm Provisions N/A 25,700,000.00 13,500,000.00 10,200,000.00
Other Noncurrent Financial Liabilities N/A 0.00 492,300,000.00 494,800,000.00
Current Liabilities N/A 601,300,000.00 924,100,000.00 915,100,000.00
Other Shortterm Provisions N/A 197,300,000.00 160,100,000.00 121,500,000.00
Trade And Other Current Payables N/A 47,000,000.00 49,200,000.00 86,600,000.00
Accruals Classified As Current N/A 107,200,000.00 133,700,000.00 135,600,000.00
Other Current Financial Liabilities N/A 224,500,000.00 0.00 0.00
Other Current Nonfinancial Liabilities N/A 6,200,000.00 16,900,000.00 N/A
Current Accrued Expenses And Other Current Liabilities N/A N/A 16,900,000.00 21,500,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Contracts With Customers 663,600,000.00 565,000,000.00 624,300,000.00
Other Income 17,600,000.00 10,900,000.00 37,800,000.00
Profit Loss From Operating Activities -19,900,000.00 -214,100,000.00 -183,900,000.00
Finance Income 60,700,000.00 38,300,000.00 74,800,000.00
Finance Costs 79,100,000.00 46,700,000.00 61,400,000.00
Profit Loss Before Tax -38,300,000.00 -222,500,000.00 -170,400,000.00
Income Tax Expense Continuing Operations 46,100,000.00 1,000,000.00 7,200,000.00
Profit (loss) -84,400,000.00 -223,500,000.00 -177,600,000.00
Profit Loss Attributable To Owners Of Parent -84,400,000.00 -223,500,000.00 -177,600,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -84,400,000.00 -223,500,000.00 -177,600,000.00
Adjustments For Decrease Increase In Inventories N/A 10,100,000.00 27,800,000.00 36,400,000.00
Other Adjustments For Noncash Items N/A -7,100,000.00 -16,800,000.00 -3,500,000.00
Interest Paid Classified As Operating Activities N/A 11,800,000.00 22,900,000.00 22,400,000.00
Interest Received Classified As Operating Activities N/A 3,000,000.00 0.00 1,400,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 600,000.00 8,200,000.00 1,500,000.00
Cash Flows From Used In Operating Activities N/A 16,800,000.00 -229,000,000.00 -156,600,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 29,400,000.00 24,700,000.00 18,800,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 160,300,000.00 28,100,000.00 5,100,000.00
Cash Flows From Used In Investing Activities N/A -189,100,000.00 -52,900,000.00 -234,700,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 27,300,000.00 0.00 N/A
Repayments Of Borrowings Classified As Financing Activities N/A 84,000,000.00 239,500,000.00 21,400,000.00
Cash Flows From Used In Financing Activities N/A -111,300,000.00 250,600,000.00 -21,400,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -283,700,000.00 -31,200,000.00 -412,800,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -27,800,000.00 30,000,000.00 40,900,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -311,500,000.00 -1,200,000.00 -371,800,000.00
Cash and cash equivalents 816,800,000.00 505,300,000.00 504,100,000.00 132,200,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
24.11.23 Charlotte Vithlani Hansson Other Buy SEK 44,640.00
08.11.23 Fredrik Järrsten Other Buy SEK 23,715.00
24.02.23 Nikolaj Arrild Sørensen Other Buy SEK 188,945.00
27.01.23 Fredrik Järrsten Other Buy SEK 79,695.00
26.07.22 Michael Matly Other Buy SEK 60,777.77
21.07.22 Charlotte Vithlani Hansson Other Buy SEK 61,500.00
15.07.22 James Noble Other Buy SEK 394,252.80
15.07.22 Staffan Lindstrand Other Buy SEK 59,995.65
14.07.22 Christine Elizabeth Rankin Other Buy SEK 60,101.90
14.06.22 Nikolaj Arrild Sørensen Other Buy SEK 182,664.00

Short Interest


Current short interest

Position Holder Short Interest in Percent Date
Armistice Capital LLC 1.79% 20.02.24
Total 1.79%

Capital markets information

ISIN

SE0000736415

LEI

549300LJ5CCWDPTK9Z08

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.